swissmedic

Public Summary SwissPAR dated 27 April 2023

Condrosulf Plus® (active substances: chondroitin sulfate and glucosamine hydrochloride)

First authorisation in Switzerland: 11 January 2023

Medicinal product (capsule) for the symptomatic treatment of knee osteoarthritis in adults

Information on authorisation

The medicinal product Condrosulf Plus, which contains the active substances chondroitin sulfate and glucosamine hydrochloride, is a hard capsule to be swallowed whole. Condrosulf Plus is used for the symptomatic treatment of knee osteoarthritis in adults with moderate to severe pain.

Condrosulf Plus was authorised under Art. 14 para. 1 let. a^{bis} of the Therapeutic Products Act (TPA). The TPA enables certain categories of medicines to be authorised according to a simplified procedure, provided this is compatible with the quality, safety and efficacy requirements and there is no conflict with Swiss interests or international obligations.

The authorisation of Condrosulf Plus is based on the medicinal product Droglican, which contains the same active substance and has been authorised for a comparable indication, dosage and use in Spain for more than 10 years.

Swissmedic assessed the quality data on the active substances and finished medicinal product but did not conduct its own comprehensive scientific review for other aspects. Efficacy and safety were only reviewed in summarised form.

The requirements for issuing a SwissPAR (Swiss Public Assessment Report) and the resulting Public Summary SwissPAR have therefore not been met. Swissmedic refers to the authorisation of the foreign comparator medicinal product:

https://www.ema.europa.eu

Further information on simplified authorisation according to Art. 14 TPA can be found in the Federal Act on Medicinal Products and Medical Devices (Therapeutic Products Act, TPA).

Further information on the medicinal product

At the time of publication of the Public Summary SwissPAR for Condrosulf Plus, the Information for healthcare professionals and the Patient information (package leaflet) were not yet available. As soon as the medicine becomes available in Switzerland, the Information for healthcare professionals and the Patient information will be made available on the following website: www.swissmedicinfo.ch.
Healthcare professionals can answer any further questions.

The date of revision of this text corresponds to that of the SwissPAR. New information concerning the authorised medicinal product in question will not be incorporated into the Public Summary SwissPAR.

Swissmedic monitors medicinal products authorised in Switzerland. Swissmedic initiates the necessary action in the event of newly discovered adverse drug reactions or other safety-relevant signals. New findings that could impair the quality, efficacy or safety of this medicinal product are recorded and published by Swissmedic. If necessary, the medicinal product information is adapted.